ARTIVION, INC. 8-K

What Happened Artivion, Inc. announced on May 18, 2026 that it completed its previously disclosed acquisition of Endospan Ltd. by exercising its option to purchase all outstanding securities of Endospan pursuant to a Securities Purchase Option Agreement (originally dated September 11, 2019, with amendments July 1, 2024 and January 9, 2026). The transaction was consummated through CryoLife Asia Pacific Pte. Ltd., a wholly owned Artivion subsidiary, and adds Endospan’s NEXUS™ Aortic Arch Stent Graft System to Artivion’s portfolio.

Key Details

• Closing date: May 18, 2026; transaction effected by exercise of the option under the existing Purchase Option Agreement and its amendments.
• Base purchase price: $175.0 million elected to be paid entirely in cash under the Agreement.
• Net cash paid: Approximately $131.3 million by CryoLife Asia Pacific after offsetting loans under the Amended and Restated Loan Agreement.
• Escrows and contingent consideration: $16.5 million deposited into an indemnity escrow and $1.0 million into an adjustment escrow; sellers are also entitled to up to $200.0 million of contingent consideration tied to future performance of Endospan’s NEXUS™ product, potentially payable ~2 years after closing.

Why It Matters This transaction expands Artivion’s product offerings into aortic repair with Endospan’s NEXUS™ system, a potentially material strategic addition to its cardiovascular portfolio. Investors should note the immediate cash outlay (net ~ $131.3M) and escrowed amounts, plus the potential earnout exposure up to $200M depending on NEXUS’s future performance. The filing also highlights customary forward-looking risk disclosures (integration risks, product performance and other uncertainties) that could affect the timing and amount of any contingent payments and the expected benefits from the acquisition.